Group 1: Industry Overview - The biopharmaceutical industry is experiencing rapid growth, leading to increased demand for consumables such as filters. The global upstream biopharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2030, reaching a market size of $44.7 billion by 2035 [1] - The global filter products market is projected to have a CAGR of 6.7% from 2020 to 2024, with a market size of $4.39 billion in 2024 [1] Group 2: Company Developments - The company has entered into a transaction agreement with Weigao Blood Purification for the acquisition of its subsidiary, Weigao Purui. The total consideration for the transaction is RMB 8.511 billion, corresponding to a static PE multiple of 14.66 for 2024 [2] - Following the transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Blood Purification, and the company will hold 52.10% of Weigao Blood Purification's shares, which will be consolidated into the company's financial statements [2] Group 3: Financial Projections - The company is expected to achieve a net profit attributable to shareholders of RMB 2.091 billion, RMB 2.287 billion, and RMB 2.507 billion for the years 2025 to 2027, reflecting year-on-year changes of 1.18%, 9.37%, and 9.62% respectively [2]
威高股份(1066.HK)：研发驱动高耗转型 平台化国际化发展